Please assess the completion status of the following clinical trial:

Trial Title: The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years of age~* anti-HCV and HCV RNA positive,~* interested in starting HCV treatment at the time of diagnosis~* Women of childbearing potential engaged in sexual activity that could lead to pregnancy~* must consent to use contraception and agree to pregnancy testing during treatment~* If currently not enrolled in insurance, agree to assistance to enroll in insurance~Exclusion Criteria:~* HBsAg positive from pre-screening visit and no medically controlled hepatitis B virus (HBV) condition~* History of hepatic decompensation (ascites, hepatic encephalopathy, or variceal hemorrhage).~* Current use of medications that is not compatible with SOF/VEL use, according to current prescribing guidelines, including amiodarone or a proton pump inhibitor exceeding 20 mg of omeprazole equivalent.~* Prior treatment with an NS5a based HCV treatment regimen with subsequent viral rebound. Participants who have clear HCV reinfection as defined by an HCV GT that is different from the original genotype may enroll. If genotype results are not available from the initial and subsequent HCV infection, the individual will not be enrolled unless participant can provide SVR-12 record confirming HCV cure.~* Pregnancy or breastfeeding.~* Life expectancy of \< 12 months as assessed by study clinical health provider.~* Late exclusion criteria: Participants with the following lab values at week 0 will be evaluated on a case by case basis for continuation of SOF/VEL at the week 2 visit~* Albumin \< 3.0~* Hemoglobin \< 8.0 (women) and \< 9.0 g/dl ( men)~* Platelet count \< 50,000~* creatinine (Cr) clearance (estimated by Cockcroft-Gault) \< 30 ml/min~* aspartate aminotransferase (AST) or Alanine Aminotransferase (ALT) \> 10 x ULN~* Total bilirubin \> 1.5x ULN (for participants on atazanavir, \> 3 x ULN), international normalized ratio (INR) \> 1. 5 x ULN

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- at Point-of-Diagnosis HCV treatment (Type: EXPERIMENTAL): At the point of HCV infection diagnosis, (HCV RNA positive and anti-HCV positive) individuals who meet eligibility criteria and elect to start HCV treatment at the same visit and monitored at two-week intervals at the community-site.
- Passive observation (Type: ACTIVE_COMPARATOR): Participants who test positive for HCV chronic infection (HCV RNA positive, and anti-HCV positive) but elect to not enroll in the intervention arm. Electronic medical record data will be reviewed for up to 2 years for HCV related care information (e.g., HCV treatment start date, end date, SVR-12).

Based on this trial design, predict the completion outcome and termination type (if applicable).